Business Wire

RS Oncology presents new drug in early clinical development for Mesothelioma and lung cancer patients

Start-up US biotech company tackling rare diseases presents three case studies in France LILLE, France--(BUSINESS WIRE)--RS Oncology is bringing exciting new science to patients who will have the best ...
ascopubs.org

First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due ...

A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors.
PharmiWeb

RS Oncology Announces Completion of First-in-Human Phase 1 Clinical Trial of RSO-021, a Novel Irreversible Inhibitor of Mitochondrial PRX3

CAMBRIDGE, Mass.--(BUSINESS WIRE)--#Lungcancer--RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, today announced the ...
PharmiWeb

RS Oncology presents new drug in early clinical development for Mesothelioma and lung cancer patients

LILLE, France--(BUSINESS WIRE)--#Lungcancer--RS Oncology is bringing exciting new science to patients who will have the best chance of benefiting from new therapies. PRX3 is a novel drug target with ...